SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 29, 2019
Five Prime Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|(state or other jurisdiction of incorporation)||(Commission File Number)||(I.R.S. Employer Identification No.)|
111 Oyster Point Boulevard
South San Francisco, California
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (415) 365-5600
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Name of Each Exchange on Which Registered
|Common Stock, par value $0.001 per share||FPRX||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 8.01|| |
On July 1, 2019, Five Prime Therapeutics, Inc. (the Company) commenced a tender offer to exchange eligible stock options for replacement stock options with modified terms pursuant to the Offer to Exchange Eligible Options for New Options, dated July 1, 2019 (the Exchange Offer). The Exchange Offer expired at 6:00 p.m., Pacific Time, on Monday, July 29, 2019.
Pursuant to the Exchange Offer, 55 employees elected to exchange outstanding options, and the Company accepted for cancellation options to purchase an aggregate of 436,648 shares of the Companys common stock (Common Stock), representing approximately 85% of the total shares of Common Stock underlying the options eligible for exchange. On July 29, 2019, immediately following the expiration of the Exchange Offer, the Company granted new options to purchase 235,419 shares of Common Stock, pursuant to the terms of the Exchange Offer and the Companys 2013 Omnibus Incentive Plan. The exercise price per share of the stock options granted pursuant to the Exchange Offer was $5.06 per share, which was the closing price per share of Common Stock on The Nasdaq Global Select Market on the grant date of such new stock options. The vesting terms of the new stock options are described in detail in the Exchange Offer.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Five Prime Therapeutics, Inc.|
|By:||/s/ Francis Sarena|
|Chief Strategy Officer and Secretary|
Dated: July 31, 2019